Get the Stockscreener App
1.32
0.00%
0.00
Bioatla Inc stock is traded at $1.32, with a volume of 19,068.
It is up +0.00% in the last 24 hours and down -60.60% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
See More
Previous Close:
$1.32
Open:
$1.25
24h Volume:
19,068
Relative Volume:
0.36
Market Cap:
$2.20M
Revenue:
$2.00M
Net Income/Loss:
$-50.62M
P/E Ratio:
-0.0316
EPS:
-41.8255
Net Cash Flow:
$-37.11M
1W Performance:
-23.92%
1M Performance:
-60.60%
6M Performance:
-84.68%
1Y Performance:
-94.71%
1-Day Range:
$1.16
$1.39
1-Week Range:
$1.07
$1.70
52-Week Range:
$1.07
$71.50
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
1.32 | 5.30M | 2.00M | -50.62M | -37.11M | -41.83 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BioAtla (BCAB) Financial Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Investor Response: Shares Finish 3.46% Higher in the Latest SessionWeak Earnings Momentum - vinanet.vn
BioAtla Inc. (BCAB) Tumbles 10.4% to $3.09 as Bearish Momentum Tests Key $2.94 SupportTurnaround Stocks - Vinanet
Bioatla Stock Price Forecast. Should You Buy BCAB? - StockInvest.us
BioAtla, Inc. Q2 2026: Revenue $6.5M, EPS $0.27— 10-Q Summary - TradingView
BioAtla (BCAB) turns Q2 2026 profit as cash falls and going concern risk emerges - Stock Titan
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Bioatla Inc (BCAB) Stock News Today - TradingKey
Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioAtla (BCAB) Climbs 3.9% to $3.46 as Buyers Step In Near SupportButterfly Setup - Vinanet
BCAB Q2'26 Earnings: EPS estimate is (8.50) USD - TradingView
BioAtla Inc. (BCAB) Slips 2.37% to $3.3 as Shares Hover Near Key Support at $3.13Quality ETF - vinanet.vn
BCAB Q4 2025 Earnings: EPS Beat Signals Tightened Cash Management Amid No Revenue MilestonesOne-Time Gain Impact - Vinanet
BCAB|Bioatla Inc|Price:3.460|Chg%:+0.130 - TradingKey
BioAtla (BCAB) Slips 3.76% as Shares Approach Critical Support ZoneGap Fill Strategy - vinanet.vn
Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioatla Inc (BCAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioAtla, Inc. Revenue Breakdown – NASDAQ:BCAB - TradingView
Bioatla Inc (BCAB) Balance Sheet - TradingKey
Bioatla Inc (BCAB) Income Statement - TradingKey
TradingKey - TradingKey
BCAB|Bioatla Inc|Price:3.280|Chg%:-0.010 - TradingKey
BCAB|Bioatla Inc|Price:3.360|Chg%:-0.010 - TradingKey
Bioatla Inc (BCAB) Institutional Confidence - TradingKey
Bioatla Inc (BCAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioAtla Inc. (BCAB) Moves Higher: Biotech Stock Tests Key Resistance at $3.63Change of Character - dars.gov.et
BioAtla Company Profile & Introduction - Moomoo
BioAtla Inc. (BCAB) Holds Near Key Support as Slight Decline Tests Investor ConvictionIron Condor Alert - vinanet.vn
BioAtla Inc. (BCAB) Edges Lower Amid Consolidation, Testing Key Support LevelsNAAIM Exposure - dars.gov.et
BioAtla Shareholders Back Directors, Auditor and Pay Plan - The Globe and Mail
BioAtla, Inc. 8-K SEC Filing: Company Profile, Key Data, and Stock Information for July 2026 - Minichart
BCAB Q4 2025 Earnings: Substantial EPS Beat Signals Progress in Development PipelineBook Value Growth - vinanet.vn
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Provides OptimismEarnings Miss Streak - DonanımHaber
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrower Net Loss Surpasses Expectations as Clinical Pipeline ProgressesBasic EPS Analysis - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock DeclinesTax Rate Impact - dars.gov.et
BioAtla Inc. (BCAB) Surges Nearly 6% as Shares Test Key Resistance LevelStraddle Setup - dars.gov.et
BCAB Q4 2025 Earnings: Narrowing Losses Beat Street Estimates as Stock Rises 4%Annual Financial Report - po-news-eg.net
Price to sales forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB) - TradingView
BCAB Forecast — Price Target — Prediction for 2027 - TradingView
BioAtla: BioAtla, Inc.Reverse Split Option Symbol: BCAB New Symbol: BCAB1 - Moomoo
BioAtla Inc. (BCAB) Jumps Over 7% as Biotech Momentum BuildsValue Area Low - dars.gov.et
Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Surprises; Shares Edge HigherEarnings Surprise Report - dars.gov.et
BioAtla (BCAB) Q4 2025 Earnings: Narrowed Loss Beats Expectations as Stock AdvancesEarnings Expansion Phase - dars.gov.et
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrowed Loss and Positive Surprise Boost Investor SentimentMargin Guidance - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Consistency Score - newsline.com
BCAB Q4 2025 Earnings: Narrower Loss Surprises, Shares RiseLow Estimate Range - newsline.com
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):